Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-chlorophenyl)-2‑[(pyridin‑4‑ylmethyl)amino]benzamide is a synthetic small molecule classified as a benzanilide derivative. It acts as an inhibitor of vascular endothelial growth factor receptors (VEGFR), specifically targeting both VEGFR1 and VEGFR2 tyrosine kinases. By inhibiting these receptors, the compound blocks downstream signaling pathways involved in angiogenesis—the formation of new blood vessels—which is a key process in tumor growth and metastasis. This mechanism makes it relevant for research into anti-cancer therapies, particularly those aimed at suppressing tumor vascularization[2][5][9]. The compound is primarily used as a biochemical tool or reference inhibitor in preclinical studies rather than as an approved pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide.